Seres Therapeutics (MCRB) said results from a phase 1b trial of SER-155 in people undergoing allogenic stem cell transplantation showed a "positive impact on biomarkers of systemic inflammation and immune homeostasis" compared with placebo.
The results back previous data showing that SER-155 "was associated with a significant reduction in bloodstream infections," the company said Thursday in a statement.
SER-155 is a live biotherapeutic designed to prevent infections in people undergoing allogenic stem cell transplantation to treat blood cancers, Seres said.
The company also said its cash runway was extended into Q1 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。